Global Partners L.P. (GLP)
NYSE NYSE Primary 
Are GLP-1 Drugs Becoming a Meaningful Revenue Driver for CAH Stock?
CAH sees GLP-1 drugs boost revenue growth, but margins lag as strong demand lifts volumes without significantly improving profitability.
Lilly GLP-1 drug rivals Novo's pipeline treatment on gut side effects but throws up skin concern
New trial data complicates the competitive picture in the fast-growing obesity drug market Eli Lilly and Co's (NYSE:LLY) experimental weight-loss and diabetes drug retatrutide has shown a side-effect profile broadly comparable to leading treatments, but new data flagging an unusual skin reaction could give prescribers pause as the race to challenge Novo Nordisk's dominance intensifies. Lilly reported headline results from the first phase three trial of retatrutide in type 2 diabetes, showing patients achieved 16.8% weight loss and a 1.1 percentage point reduction in HbA1c, a standard measure of long-term blood sugar control, after 40 weeks at the 12mg dose.
Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says
Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes.
Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum?
LLY stock falls 6% after an HSBC downgrade flagged persisting U.S. pricing pressure, rising market competition and compounded tirzepatide risks, despite strong GLP-1 demand.
Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target
Structure Therapeutics (GPCR) reported highly positive Phase 2 ACCESS II data for aleniglipron, achieving ~16% placebo-adjusted weight loss with strong statistical significance and no plateau. Aleniglipron's oral, non-peptide, once-daily profile with injectable-level efficacy and improved tolerability positions GPCR as a potential best-in-class oral GLP-1 therapy. GPCR's $1.4B cash position funds operations into 2028, supporting Phase 3 development and pipeline expansion without immediate dilution risk.
3 Companies at the Forefront of the GLP-1 Pill Wars
Though the first GLP-1 agonists date back more than 20 years, it's only in the last couple of years that they began to dominate the pharmaceutical space for their massive potential as weight loss drugs. With some estimates placing the market at nearly $63 billion in early 2026, forecasts call for the GLP-1 industry to roughly triple over the coming decade.
Eli Lilly's Employer Push Could Unlock New GLP-1 Demand
The world's most valuable pharmaceutical stock, Eli Lilly and Company NYSE: LLY, has continued to assert its dominance in the weight-loss and diabetes drug market in 2026.
Will Policy Shifts Accelerate Demand for Eli Lilly's GLP-1 Drugs?
LLY is likely to see stronger demand for its GLP-1 drugs as Medicare expands coverage and the company prepares to launch an oral obesity treatment.
Can Novo Nordisk's Hims & Hers Deal Revive Its GLP-1 Momentum?
NVO partners with HIMS to expand access to Ozempic and Wegovy via telehealth, aiming to shift patients from compounded GLP-1s to FDA-approved drugs.
Hims & Hers Health: The GLP-1 Chaos Is Fading, The Thesis Is Still On Track
Hims & Hers Health, Inc. surges after securing a partnership with Novo Nordisk, resolving legal and regulatory overhangs tied to compounded GLP-1s. HIMS's long-term platform thesis centers on becoming the go-to digital health platform, leveraging subscriber growth, data, and strategic partnerships for expansion. Despite near-term margin pressures and slower growth, HIMS trades at a compelling valuation with 2030 EV/EBITDA of 3.7 and significant upside if targets are met.
GLP-1 weight-loss drug race heats up as new rival matches Wegovy results with fewer side effects
Citi stays 'neutral' on Novo Nordisk as crowded obesity market threatens to erode its competitive edge Novo Nordisk (NYSE:NVO), the Danish pharma giant behind the Ozempic and Wegovy weight-loss drugs, faces a tightening competitive landscape after a US rival published late-stage trial data showing comparable efficacy to its flagship products with a better side-effect profile. Regeneron's weekly injectable GIP/GLP-1 agonist, a drug that mimics gut hormones to suppress appetite, achieved 19% weight loss at 48 weeks in a Chinese phase III trial, matching the performance of Eli Lilly's Zepbound at the same time point but with lower gastrointestinal toxicity.
FDA Warns Novo Nordisk of Unreported Side Effects Tied to GLP-1 Patients
The FDA underscored cases including two deaths and a suicide linked to patients taking semaglutide, which Novo markets as Ozempic and Wegovy.
